3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Tumor Lysis Syndrome
2
Lymphoma
1
Leukemia
1
Inflammation
1
Hyperuricemia
1
Hematologic Neoplasms
1
Gout
1
Cardiovascular Diseases
1
Arthritis
1
Interventions
Cyclophosphamide
34
fludarabine
25
fludarabine phosphate
24
Tacrolimus
24
Mycophenolic Acid
23
Whole-Body Irradiation
22
Busulfan
15
Methotrexate
12
Melphalan
12
Granulocyte Colony-Stimulating Factor
12
Antilymphocyte Serum
12
thymoglobulin
11
Cyclosporine
11
Stem Cell Transplantation
10
Filgrastim
10
Rituximab
9
Thiotepa
7
Peripheral Blood Stem Cell Transplantation
7
Nivolumab
7
Dexamethasone
7
trametinib
6
Radiotherapy
6
Mesna
6
Cytarabine
6
Prednisone
5
Calcium Dobesilate
5
Bortezomib
5
Azacitidine
5
Alemtuzumab
5
Voriconazole
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hematologic Neoplasms
×
Febuxostat
×
Clear all
NCT03605212
2021-06-03
FLORET
Menarini Group
Phase 1/2
Terminated
30 enrolled
14 charts